Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication.

Prestwich RJ, Ilett EJ, Errington F, Diaz RM, Steele LP, Kottke T, Thompson J, Galivo F, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA.

Clin Cancer Res. 2009 Jul 1;15(13):4374-4381. doi: 10.1158/1078-0432.CCR-09-0334. Epub 2009 Jun 9.

2.

Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer.

Chang CL, Ma B, Pang X, Wu TC, Hung CF.

Mol Ther. 2009 Aug;17(8):1365-72. doi: 10.1038/mt.2009.118. Epub 2009 May 26.

3.

Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.

Lun XQ, Jang JH, Tang N, Deng H, Head R, Bell JC, Stojdl DF, Nutt CL, Senger DL, Forsyth PA, McCart JA.

Clin Cancer Res. 2009 Apr 15;15(8):2777-88. doi: 10.1158/1078-0432.CCR-08-2342. Epub 2009 Apr 7.

4.

Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4).

Elkord E, Dangoor A, Burt DJ, Southgate TD, Daayana S, Harrop R, Drijfhout JW, Sherlock D, Hawkins RE, Stern PL.

Cancer Immunol Immunother. 2009 Oct;58(10):1657-67. doi: 10.1007/s00262-009-0674-y. Epub 2009 Feb 17.

PMID:
19221742
5.

Cancer vaccines: will we ever learn?

Johnson RS, Walker AI, Ward SJ.

Expert Rev Anticancer Ther. 2009 Jan;9(1):67-74. doi: 10.1586/14737140.9.1.67.

PMID:
19105708
6.

Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer.

Kirn DH, Thorne SH.

Nat Rev Cancer. 2009 Jan;9(1):64-71. doi: 10.1038/nrc2545. Review.

PMID:
19104515
7.

Virus combinations and chemotherapy for the treatment of human cancers.

Kumar S, Gao L, Yeagy B, Reid T.

Curr Opin Mol Ther. 2008 Aug;10(4):371-9. Review.

PMID:
18683102
8.

Translation of targeted oncolytic virotherapeutics from the lab into the clinic, and back again: a high-value iterative loop.

Liu TC, Hwang TH, Bell JC, Kirn DH.

Mol Ther. 2008 Jun;16(6):1006-8. doi: 10.1038/mt.2008.70. No abstract available.

9.

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.

Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, Oh SY, Han SY, Yoon JH, Hong SH, Moon A, Speth K, Park C, Ahn YJ, Daneshmand M, Rhee BG, Pinedo HM, Bell JC, Kirn DH.

Lancet Oncol. 2008 Jun;9(6):533-42. doi: 10.1016/S1470-2045(08)70107-4. Epub 2008 May 19. Erratum in: Lancet Oncol. 2008 Jul;9(7):613.

PMID:
18495536
10.

Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma.

Gulley JL, Arlen PM, Tsang KY, Yokokawa J, Palena C, Poole DJ, Remondo C, Cereda V, Jones JL, Pazdur MP, Higgins JP, Hodge JW, Steinberg SM, Kotz H, Dahut WL, Schlom J.

Clin Cancer Res. 2008 May 15;14(10):3060-9. doi: 10.1158/1078-0432.CCR-08-0126.

11.

Enhancing poxvirus oncolytic effects through increased spread and immune evasion.

Kirn DH, Wang Y, Liang W, Contag CH, Thorne SH.

Cancer Res. 2008 Apr 1;68(7):2071-5. doi: 10.1158/0008-5472.CAN-07-6515.

12.

Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery.

Thorne SH, Contag CH.

Gene Ther. 2008 May;15(10):753-8. doi: 10.1038/gt.2008.42. Epub 2008 Mar 20. Review.

PMID:
18356814
13.

Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses.

Guo ZS, Thorne SH, Bartlett DL.

Biochim Biophys Acta. 2008 Apr;1785(2):217-31. doi: 10.1016/j.bbcan.2008.02.001. Epub 2008 Feb 15. Review.

14.

Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors.

Qiao J, Wang H, Kottke T, Diaz RM, Willmon C, Hudacek A, Thompson J, Parato K, Bell J, Naik J, Chester J, Selby P, Harrington K, Melcher A, Vile RG.

Gene Ther. 2008 Apr;15(8):604-16. doi: 10.1038/sj.gt.3303098. Epub 2008 Feb 28.

15.

Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.

Kirn DH, Wang Y, Le Boeuf F, Bell J, Thorne SH.

PLoS Med. 2007 Dec;4(12):e353.

16.

Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy.

Qiao J, Kottke T, Willmon C, Galivo F, Wongthida P, Diaz RM, Thompson J, Ryno P, Barber GN, Chester J, Selby P, Harrington K, Melcher A, Vile RG.

Nat Med. 2008 Jan;14(1):37-44. Epub 2007 Dec 9.

PMID:
18066076
17.

Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963.

Thorne SH, Hwang TH, O'Gorman WE, Bartlett DL, Sei S, Kanji F, Brown C, Werier J, Cho JH, Lee DE, Wang Y, Bell J, Kirn DH.

J Clin Invest. 2007 Nov;117(11):3350-8.

18.

Combining immune cell and viral therapy for the treatment of cancer.

Thorne SH, Contag CH.

Cell Mol Life Sci. 2007 Jun;64(12):1449-51. Review.

PMID:
17404689
19.

Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus.

Lorence RM, Roberts MS, O'Neil JD, Groene WS, Miller JA, Mueller SN, Bamat MK.

Curr Cancer Drug Targets. 2007 Mar;7(2):157-67. Review.

PMID:
17346107
20.

Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress.

Liu TC, Galanis E, Kirn D.

Nat Clin Pract Oncol. 2007 Feb;4(2):101-17. Review.

PMID:
17259931

Supplemental Content

Support Center